Actualités

June 25 () - Merck KGaA has agreed to ‌acquire biotech firm Bio-Techne ‌Corp for $11.3 billion, the German science ​and healthcare firm said in a statement on Thursday.

Merck KGaA offered $73 a share in cash for Bio-Techne, representing a 24% premium to the U.S. lab-tools supplier’s closing price Wednesday.

Bank of America has predicted that the Federal Reserve will be forced to raise interest rates by 75 basis points this year, with the first 25-basis-point hike in September. They also see additional 25-basis-point hikes in October and December. The energy shock from the war with Iran drove inflation higher, with the CPI rising in ... Bank of America Sees Interest Rates Exploding Higher Soon: Play It Safe With 4 Dividend Giants

U.S. stocks rose in early Thursday trading, rebounding from the previous session’s Fed-driven selloff as falling oil prices and optimism surrounding the Iran peace deal boosted investor sentiment.

SpaceX’s $75 billion initial public offering shattered market records, turned founder Elon Musk into the world’s first trillionaire, and opened fresh debates over corporate valuations and governance. It’s not the first time an IPO has shaken things up. IPOs have been reshaping markets since the Bank of North America’s 1783 debut got it all started for the young republic.

Gain insight on Roche, Zealand Pharma and more in the latest Market Talks covering the health care sector.

Phibro trades near 10x forward earnings vs higher peer multiples as strong Q3 beat, margin gains and 2026 guidance support a modest upside case.

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

US stocks were expected to head in different directions on Thursday morning, as oil prices retreat but tech earnings overnight disappointed investors. Dow Jones futures were called 0.8% higher, but the S&P 500 was off 0.4% and Nasdaq futures were down 1.3%. The latter pair were...

CHICAGO, June 1 (Reuters) - Merck is in discussions with various global health authorities about making its COVID antiviral pill molnupiravir ‌available as an Ebola treatment to address the widening outbreak in ‌the Democratic Republic of Congo, a senior executive told Reuters. The outbreak, which has so far infected ​a suspected 1,100 people and resulted in 42 deaths, involves a rare strain of the virus called Bundibugyo for which there are no approved vaccines or treatments.

Stock Market Today: The Dow Jones index rose Monday amid ongoing hopes for a U.S.-Iran deal. Nvidia stock jumped on a new chip.

Futures fell as AI leaders Micron, Sandisk and more keep sliding. Home Depot beat views while Google I/O kicks off.

Shares of Regeneron Pharmaceuticals are down about 11%, dragging the Nasdaq composite, after the company’s experimental melanoma drug failed a pivotal clinical trial. The company said that its drug fianlimab, when combined with an approved cancer drug, didn't keep patients’ disease from worsening significantly longer than Merck’s Keytruda.

Shares tumbled after the drugmaker said a late-stage clinical trial of a skin cancer medication fell short of its target.

By Twesha Dikshit, Avinash P and Johann M Cherian May 13 (Reuters) - European shares ended higher on Wednesday, led by gains in mining stocks, though caution lingered as investors weighed the economic

Merck KGaA (ETR:MRK) reported what executives described as a “solid start” to 2026, with organic growth in its Life Science and Electronics businesses offsetting a decline in Healthcare, and raised its full-year outlook after stronger momentum late in the quarter. Group Chief Executive Officer Kai

Find insight on Merck KGaA, IHH Healthcare and more in the latest Market Talks covering the health care sector.

The outlook lift comes on expectations of stronger momentum in the group’s life-sciences unit, resilience in healthcare, as well as its first-quarter performance and market conditions.

Moby summary of Codexis, Inc.'s Q1 2026 earnings call

Elizabeth Schwartz will head up government relations at the for-profit hospital trade association as health systems brace for federal funding cuts.

Codexis (NASDAQ:CDXS) reported first-quarter 2026 revenue of $15.2 million, up from $7.5 million a year earlier, as the company highlighted continued progress commercializing its ECO Synthesis enzymatic manufacturing platform for RNA medicines and reiterated full-year revenue guidance of $72 million

May 4 (Reuters) - Global drugmakers have been ramping up U.S. manufacturing and stockpiling inventory as the Trump administration moves to impose 100% tariffs on branded drugs unless companies cut